TAUG - Tauriga to resume clinical work for pharmaceutical-grade Tauri-Gum
Tauriga Sciences (TAUG) announces the resumption of clinical development for its proposed “Anti-Nausea” pharmaceutical-grade version of Tauri-Gum™. The company, focused on the Cannabidiol and Cannabigerol Edibles market, filed a provisional U.S. patent in March covering the pharmaceutical-grade version of Tauri-Gum™.Tauriga calls the delivery system for the proposed product as a ’modified version (substantially higher concentration of CBD) of the existing “Tauri-Gum™” chewing gum formulation’.In addition to the clinical development of Tauri-Gum™, the company has collaborated with Aegea Biotechnologies to develop a rapid, multiplexed, Novel Coronavirus (COVID-19) test.
For further details see:
Tauriga to resume clinical work for pharmaceutical-grade Tauri-Gum